Racivir

Medication
  • none
Identifiers
  • 4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
CAS Number
  • 137530-41-7
PubChem CID
  • 454858
ChemSpider
  • 400521
UNII
  • 9PDN1V466A
NIAID ChemDB
  • 005245
CompTox Dashboard (EPA)
  • DTXSID701288260 Edit this at Wikidata
Chemical and physical dataFormulaC8H10FN3O3SMolar mass247.24 g·mol−13D model (JSmol)
  • Interactive image
  • c1c(c(nc(=O)n1[C@H]2CS[C@H](O2)CO)N)F
InChI
  • InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1
  • Key:XQSPYNMVSIKCOC-RITPCOANSA-N

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely used NRTI

References

  1. ^ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.


  • v
  • t
  • e
  • v
  • t
  • e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1st generation
2nd generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1st generation
2nd generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
  • Tat antagonists
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.